Global Congestive Heart Failure – Epidemiology Insights and Forecast Report (Top 32 Markets) – 2020 To 2040

Global Congestive Heart Failure Epidemiology Insights

Thelansis’s “Global Congestive Heart Failure Epidemiology Insights and Forecast Report (Top 32 Markets) – 2020 To 2040″ provides an analysis of disease burden, characterized by disease definition, kidney biopsy cases, prevalence, incidence, diagnosed cases, severity, comorbidities, and clinical manifestations. Potential patient flow dynamics in disease burden are driven by shifts in demographic indicators and their correlation with age and gender distribution over time. Changes in the reported cases and long-term survival of patients may depend on diet, lifestyle, comorbid conditions, and the availability of interventions or therapies for the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America).

Congestive Heart Failure Overview

Heart failure, often referred to as congestive heart failure (CHF), is a chronic clinical syndrome in which the heart is unable to pump sufficient blood to meet the body’s metabolic demands or can do so only at the expense of elevated filling pressures. This dysfunction leads to fluid accumulation, causing pulmonary and systemic congestion. It is commonly categorized into heart failure with reduced ejection fraction (HFrEF), reflecting impaired contraction, and heart failure with preserved ejection fraction (HFpEF), reflecting impaired relaxation and filling. Major causes include hypertension, coronary artery disease, valvular disease, and cardiomyopathies. Patients typically present with dyspnea, orthopnea, fatigue, and peripheral edema, while examination may reveal jugular venous distention and pulmonary rales. Management follows Guideline‑Directed Medical Therapy (GDMT), centered on four pillars—ARNIs or ACE inhibitors, beta‑blockers, mineralocorticoid receptor antagonists, and SGLT2 inhibitors—with diuretics used to control fluid overload and reduce hospitalization risk.

Market Definition:

• North America (United States, Canada)
• Europe (Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Norway, Poland, Portugal, Russia, Spain, Sweden, Switzerland, United Kingdom)
• Middle East (Saudi Arabia, UAE, Kuwait, Turkey)
• Asia Pacific (Australia, China, Hong Kong, India, Indonesia, Japan, Malaysia, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand, Vietnam)
• Africa (Egypt, Nigeria, South Africa, Morocco)
• South / Latin America (Argentina, Brazil, Chile, Colombia, Mexico, Peru)

Deliverables format and updates*:

• Access to an interactive epidemiology platform with downloadable Excel and PPT files.
• Global findings
• G8 findings
• Regional findings
• Country-specific findings
• Others*: regular updates, customizations, epidemiologist support
• *As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the content. Countries, subpopulations, and years of forecast can be customized as per client requirements.

Key business questions answered:

• 20-year historical and forecast data (2020–2040)
• Disease definition based on globally accepted and latest criteria (e.g., ICD-10 codes)
• Granular patient population coverage by year and geography
• Detailed segmentation by age, gender, subpopulations, comorbidities, line of therapies, etc.
• Patient funnels
• Country comparisons
• Relevant clinical variables (e.g., staging/classification/severity)
• Insights driven by robust research and estimates:
• Published literature (e.g., peer-reviewed journal articles, registries, national surveys)
• Primary market research with KOLs
• RWD analysis using claims and EHR datasets
• Proprietary mathematical models (e.g., incidence-survival model; incidence- recurrence/progression-survival model)

Read more: Global Congestive Heart Failure – Epidemiology Insights and Forecast Report (Top 32 Markets) – 2020 To 2040